Actively Recruiting
Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease
Led by University Hospital, Lille · Updated on 2026-05-22
450
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are comparing the levels of pro-inflammatory cytokines in patients with alcoholic hepatitis to those in two other groups: patients with alcoholic cirrhosis and patients without chronic liver disease. The study aims to understand the inflammatory profiles and regenerative potential in alcoholic liver disease. This comparison may help clarify differences in immune response and liver regeneration among these groups. The study involves collecting liver biopsies and blood samples from three groups: patients with acute alcoholic hepatitis, patients with alcoholic cirrhosis, and patients without chronic liver disease. Each group undergoes tissue and blood collection to analyze inflammatory markers and genetic variants related to liver disease. These samples will be examined for proinflammatory cytokine expression, cell damage markers, and regeneration indicators. Participants will have their liver tissue and blood tested at baseline to assess inflammation and liver cell changes. Researchers will measure expression of specific cytokines, genetic variants, and markers of cell death and regeneration. The study does not involve randomization or masking. It is expected to continue through September 2027, with detailed lab analyses guiding the understanding of liver disease progression and immune responses.
CONDITIONS
Brief Title
Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with acute alcoholic hepatitis showing histological evidence of hepatocellular lesions and inflammatory infiltrate
- Active alcohol abuse as defined by DSM IV with excessive consumption before admission (>60 g/day for men, >40 g/day for women)
- Moderate elevation of transaminases (less than 500 U/L) with ASAT/ALAT ratio of 2:1
- Bilirubin level greater than 50 mg/l
- Absence of autoimmune liver disease and negative tests for hepatitis B, hepatitis C, and HIV
- Patients with alcoholic cirrhosis defined by biopsy or clinical-biological criteria
- Patients without chronic liver disease requiring blood and liver sampling for other conditions
- Age between 18 and 70 years
You will not qualify if you...
- Patients with hepatocellular carcinoma or progressive non-hepatic cancer in groups A and B1
- Presence of hepatitis B surface antigen (HBsAg)
- Positive hepatitis C antibodies by PCR
- Positive HIV 1 or 2 antibodies
- Pregnant individuals
- Patients with alcoholic liver disease excluded from group B2
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline
Participants provide liver biopsies and blood samples to compare inflammatory profiles and regenerative potential.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Hôpital Claude Huriez, CHRU
Lille, France
Actively Recruiting
Research Team
P
Philippe Mathurin, MD,PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here